Advocacy intelligence hub — real-time data for patient organizations
Bayer
Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
Novartis Pharmaceuticals — PHASE2
Mundo Sano Foundation
InCor Heart Institute — NA
Laboratorio Elea Phoenix S.A. — PHASE3
University of Sao Paulo General Hospital — PHASE1, PHASE2
University of Sao Paulo General Hospital — PHASE3
LAMPIT: FDA approved
LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
LAMPIT
Bayer
LAMPIT
(nifurtimox)Orphan drugBayer HealthCare Pharmaceuticals, Inc.
12.1 Mechanism of Action Nifurtimox is an antiprotozoal drug [see Microbiology ( 12.4 )] . Mechanism of Action The mechanism of action of nifurtimox i...
Pierre Buekens, MD, PhD
Tulane SPHTM
Felix José JA Ramires, MD,PhD
Instituto do Coração - INCORHCFMUSP
Joaquim Gascón, MD
Centro de Salud Internacional, Hospital Clínico de Barcelona ISGlobal - Barcelona Institute for Global Health
Israel Molina, PhD, M.D
Hospital Universitario Vall d'Hebron Research Institute
📍 CAMBRIGE, MA
Joaquim Gascón, PhD
Barcelona Centre for International Health Research (CRESIB)
Mauricio I Scanavacca, MD, PhD
University of São Paulo General Hospital